Compare IKT & RC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IKT | RC |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.9M | 272.6M |
| IPO Year | 2020 | 2011 |
| Metric | IKT | RC |
|---|---|---|
| Price | $1.65 | $1.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 7 |
| Target Price | ★ $5.55 | $1.50 |
| AVG Volume (30 Days) | 559.3K | ★ 1.6M |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 3.64% |
| EPS Growth | ★ 57.76 | 45.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $1.06 |
| 52 Week High | $2.61 | $3.24 |
| Indicator | IKT | RC |
|---|---|---|
| Relative Strength Index (RSI) | 25.79 | 36.79 |
| Support Level | $1.59 | $1.08 |
| Resistance Level | $1.74 | $1.88 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 4.85 | 24.14 |
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Ready Capital Corp is a real estate finance company that originates, acquires, finances, and services LMM loans, SBA loans, construction loans, USDA loans and, to a lesser extent, MBS collateralized mainly by LMM loans or other real estate-related investments. Its loans are used by businesses to purchase real estate used in their operations or by investors seeking to acquire multi-family, office, retail, mixed use or warehouse properties. It operates through two segments: LMM Commercial Real Estate, which originates LMM loans across the life-cycle of an LMM property including construction, bridge, stabilized and agency loan channels, and Small Business Lending, which acquires, originates and services owner-occupied loans guaranteed by the SBA and also originates and services USDA loans.